HER-2/neu expression in primary breast cancer with sentinel lymph node metastasis

Annals of Surgical Oncology

Volumn 13, Issue 2, 2006, Pages 205-213

  Nathanson, S David ^a   Slater, Robert ^a   DeBruyn, Deborah ^a   Kapke, Alissa ^a   Linden, Michael ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Breast cancer; HER 2 neu; Prediction; Sentinel lymph nodes

Indexed keywords

MOLECULAR MARKER;

ADULT; AGED; ANALYTIC METHOD; BREAST CANCER; CLINICAL STUDY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; IMMUNOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ONCOGENE NEU; PATHOGENESIS; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; REVIEW; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; LOGISTIC MODELS; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY;

EID: 31544452335     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.03.032     Document Type: Review

References (35)

1. Albertini JJ, Lyman GH, Cantor A, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276:1818-22.
2. Olson JA Jr, Fey J, Winawer J, et al. Sentinel lymphadenectomy accurately predicts nodal status in T2 breast cancer. J Am Coll Surg 2000; 191:593-9.
3. Noguchi M. Sentinel lymph node biopsy and breast cancer. Br J Surg 2002; 89:21-34.
4. Edge SB, Niland JC, Bookman MA, et al. Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst 2003; 95:1514-21.
5. Maggard MA, Lane KE, O'Connell JB, et al. Beyond the clinical trials: how often is sentinel lymph node dissection performed for breast cancer? Ann Surg Oncol 2005; 12: 41-7.
6. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349:546-53.
7. Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 489-514.
8. Schwartz GF, Giuliano AE, Veronesi U. The consensus conference committee: proceedings of the consensus conference of the role of sentinel lymph node biopsy in carcinoma of the breast. April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 2002; 94:2542-51.
9. Grube BJ, Hansen NM, Ye X, Giuliano AE. Tumor characteristics predictive of sentinel node metastases in 105 consecutive patients with invasive lobular carcinoma. Am J Surg 2002; 184:372-6.
10. Rivadeneira MD, Rache M, Simmons MD, et al. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg 2000; 191:1-6.
11. Olivotto I, Jackson J, Matas D, et al. Prediction of axillary lymph node involvement of women with invasive breast carcinoma: a multivariate analysis. Cancer 1998; 83:948-55.
12. Fein D, Fowble B, Hanlon A, et al. Identification of women with T1-T2 breast cancer at low risk of positive axillary nodes. J Surg Oncol 1997; 65:34-9.
13. Chen M, Palleschi S, Khoynezhad A, et al. Role of primary breast cancer characteristics in predicting positive sentinel lymph node biopsy results: a multivariate analysis. Arch Surg 2002; 137:606-9.
14. Cady B. Simplification of breast cancer surgery. Ann Surg Oncol 2005; 12:6-8.
15. Mendez JE, Fey JV, Cody H, et al. Can sentinel lymph node biopsy be omitted in patients with favorable breast cancer histology? Ann Surg Oncol 2005; 12:24-8.
16. van de Vijver MJ, He YD, van't Veer IJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009.
17. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-80.
18. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using a recombinant humanized anti-p185HER-2/neu monoclonal antibody plus cisplatinum in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16:2659-69.
19. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16:413-28.
20. Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer 2003; 98:413-23.
21. Yang W, Klos K, Yang Y, et al. ErbB2 over expression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 2002; 94:2855-61.
22. Nathanson SD, Wachna DL, Gilman D, et al. Pathways of lymphatic drainage from the breast. Ann Surg Oncol 2001; 8:837-43.
23. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73:13-22.
24. Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-30.
25. Choi SH, Barsky SH, Chang HR. Clinicopathologic analysis of sentinel lymph node mapping in early breast cancer. Breast J 2003; 9:153-62.
26. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein over expression in primary breast cancer. J Clin Oncol 1990; 8:103-10.
27. Schechter AL, Hung MC, Vaidyanathan L, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985; 229: 976-8.
28. Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 1997; 15:1-8.
29. Charpin C, Garcia S, Bouvier C, et al. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. Br J Cancer 1997; 75:1667-73.
30. Lovekin C, Ellis IO, Locker A, et al. C-erb-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991; 63:439-43.
31. DiGiovanna MP, Stern DF, Edgerton SM, et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005; 6:1152-60.
32. Konecny GE, Meng Y, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004; 10:1706-16.
33. Linderholm B, Grankvist K, Wilking N, et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000; 18:1423-31.
34. Manders P, Beex LV, Tjan-Heijnen VC, et al. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer 2002; 87:772-8.
35. Zeillinger R, Kury F, Czerwenka K, et al. Her-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 1989; 4:109-14.